Agency’s new top lawyer brings deep knowledge of drug regulatory and legislative matters from her time on Capitol Hill and strong ties to the White House, where she has worked as special assistant and senior associate counsel to President Trump since early 2017.
The US FDA’s incoming chief counsel, Stacy Cline Amin, brings deep knowledge of drug regulatory and legislative matters, as well as strong ties to the Trump White House and Capitol Hill.
Amin will join the agency Sept. 17 as chief counsel. She moves over to FDA’s White Oak headquarters from the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
